Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: Changing the apoptotic balance

Lancet Oncology

Volumn 6, Issue 8, 2005, Pages 589-598

  Hougardy, Brigitte M T ^a   Maduro, John H ^a   van der Zee, Ate G J ^a   Willemse, Pax H B ^a   de Jong, Steven ^a   de Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN E6; PROTEIN E7; PROTEIN P53; RECOMBINANT FAS LIGAND; RECOMBINANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SC 326; SMALL INTERFERING RNA; SOMATOMEDIN RECEPTOR; SULINDAC SULFIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MONOTHERAPY; MULTIPLE MYELOMA; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; RISK ASSESSMENT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; STROKE; UTERINE CERVIX CANCER; WART VIRUS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; FEMALE; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 22944491515     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70281-3     Document Type: Review

References (74)

1. Frazer I.H. Prevention of cervical cancer through papillomavirus vaccination Nat. Rev. Immunol. 2004 4 46-54
2. Green J.A. Kirwan J.M. Tierney J.F. et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis Lancet 2001 358 781-786
3. Maduro J.H. Pras E. Willemse P.H. de Vries E.G. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer Cancer Treat. Rev. 2003 29 471-488
4. Vogelstein B. Lane D. Levine A.J. Surfing the p53 network Nature 2000 408 307-310
5. Yu J. Zhang L. The transcriptional targets of p53 in apoptosis control Biochem. Biophys. Res. Commun. 2005 331 851-858
6. Sprick M.R. Rieser E. Stahl H. et al. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8 EMBO J. 2002 21 4520-4530
7. Van Geelen C.M. de Vries E.G. de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: Paving the road to patient-tailored therapy Drug Resist. Updat. 2004 7 345-358
8. Fischer B. Coelho D. Dufour P. et al. Caspase 8-mediated cleavage of the pro-apoptotic BCL-2 family member BID in p53-dependent apoptosis Biochem. Biophys. Res. Commun. 2003 306 516-522
9. Liedtke C. Groger N. Manns M.P. Trautwein C. The human caspase-8 promoter sustains basal activity through SP1 and ETS-like transcription factors and can be up-regulated by a p53-dependent mechanism J. Biol. Chem. 2003 278 27593-27604
10. Sax J.K. Fei P. Murphy M.E. et al. BID regulation by p53 contributes to chemosensitivity Nat. Cell Biol. 2002 4 842-849
11. Rikhof B. Corn P.G. El Deiry W.S. Caspase 10 levels are increased following DNA damage in a p53-dependent manner Cancer Biol. Ther. 2003 2 707-712
12. Huh J.J. Wolf J.K. Fightmaster D.L. et al. Transduction of adenovirus-mediated wild-type p53 after radiotherapy in human cervical cancer cells Gynecol. Oncol. 2003 89 243-250
13. Aguilar-Lemarroy A. Kirchhoff S. Whitaker N. et al. Differential sensitivity of human papillomavirus type 16(+) and type 18(+) cervical carcinoma cells to CD95-mediated apoptosis Int. J. Cancer 2001 93 823-831
14. Lee M.W. Park S.C. Kim J.H. et al. The involvement of oxidative stress in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in HeLa cells Cancer Lett. 2002 182 75-82
15. Leverkus M. Neumann M. Mengling T. et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes Cancer Res. 2000 60 553-559
16. Wajant H. TRAIL and NFκB signaling-a complex relationship Vitam Horm 2004 67 101-132
17. Reesink-Peters N. Hougardy B.M.T. van den Heuvel F.A.J. et al. Death receptors and ligands in cervical carcinogenesis: An immunohistochemical study Gynecol. Oncol. 2004 96 705-713
18. Strand S. Hofmann W.J. Hug H. et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: A mechanism of immune evasion? Nat. Med. 1996 2 1361-1366
19. Cheung T.H. Chung T.K. Lo K.W. et al. Apoptosis-related proteins in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix Gynecol. Oncol. 2002 86 14-48
20. Isacson C. Kessis T.D. Hedrick L. Cho K.R. Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type Cancer Res. 1996 56 669-674
21. Schneider P. Holler N. Bodmer J.L. et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity J. Exp. Med. 1998 187 1205-1213
22. Walczak H. Miller R.E. Ariail K. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat. Med. 1999 5 157-163
23. Adams J. The proteasome: A suitable antineoplastic target Nat. Rev. Cancer 2004 4 349-360
24. Shackelford J. Pagano J.S. Tumor viruses and cell signaling pathways: Deubiquitination versus ubiquitination Mol. Cell Biol. 2004 24 5089-5093
25. Aguilar-Lemarroy A. Gariglio P. Whitaker N.J. et al. Restoration of p53 expression sensitizes human papillomavirus type 16 immortalized human keratinocytes to CD95-mediated apoptosis Oncogene 2002 21 165-175
26. Mantovani F. Banks L. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines Oncogene 1999 18 3309-3315
27. Voorhees P.M. Dees E.C. O'Neil B. Orlowski R.Z. The proteasome as a target for cancer therapy Clin. Cancer Res. 2003 9 6316-6325
28. Sunwoo J.B. Chen Z. Dong G. et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma Clin. Cancer Res. 2001 7 1419-1428
29. Russo S.M. Tepper J.E. Baldwin Jr. A.S. et al. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-κB Int. J. Radiat. Oncol. Biol. Phys. 2001 50 183-193
30. Lenz H.J. Clinical update: Proteasome inhibitors in solid tumors Cancer Treat. Rev. 2003 29 SUPPlL. 1 41-48
31. Hall A.H. Alexander K.A. RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells J. Virol. 2003 77 6066-6069
32. Yoshinouchi M. Yamada T. Kizaki M. et al. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA Mol. Ther. 2003 8 762-768
33. Song E. Lee S.K. Wang J. et al. RNA interference targeting Fas protects mice from fulminant hepatitis Nat. Med. 2003 9 347-351
34. Jiang M. Rubbi C.P. Milner J. Gel-based application of siRNA to human epithelial cancer cells induces RNAi-dependent apoptosis Oligonucleotides 2004 14 1-10
35. Williams C.S. Mann M. DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development Oncogene 1999 18 7908-7916
36. Zha S. Yegnasubramanian V. Nelson W.G. et al. Cyclooxygenases in cancer: Progress and perspective Cancer Lett. 2004 215 1-20
37. Kim K.Y. Seol J.Y. Jeon G.A. Nam M.J. The combined treatment of aspirin and radiation induces apoptosis by the regulation of bcl-2 and caspase-3 in human cervical cancer cell Cancer Lett. 2003 189 157-166
38. Ogino M. Minoura S. Indomethacin increases the cytotoxicity of cis-platinum and 5-fluorouracil in the human uterine cervical cancer cell lines SKG-2 and HKUS by increasing the intracellular uptake of the agents Int. J. Clin. Oncol. 2001 6 84-89
39. Alshafie G.A. Abou-Issa H.M. Seibert K. Harris R.E. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model Oncol. Rep. 2000 7 1377-1381
40. Choy H. Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A rational advance? J. Natl. Cancer Inst. 2003 95 1440-1452
41. Kim S.H. Song S.H. Kim S.G. et al. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-κB as a possible target J. Cancer Res. Clin. Oncol. 2004 130 551-560
42. Zhang L. Yu J. Park B.H. et al. Role of BAX in the apoptotic response to anticancer agents Science 2000 290 989-992
43. Kulkarni S. Rader J.S. Zhang F. et al. Cyclooxygenase-2 is overexpressed in human cervical cancer Clin. Cancer Res. 2001 7 429-434
44. Kim Y.B. Kim G.E. Pyo H.R. et al. Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix Int. J. Radiat. Oncol. Biol. Phys. 2004 60 822-829
45. Kim Y.B. Kim G.E. Cho N.H. et al. Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy Cancer 2002 95 531-539
46. Nagai N. Tian X. Mukai K. et al. Overexpression of cyclooxygenase-2 protein and its relationship to apoptosis in cervical carcinoma treated with neoadjuvant chemotherapy Int. J. Mol. Med. 2003 12 709-714
47. Ferrandina G. Ranelletti F.O. Legge F. et al. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: A pilot study Clin. Cancer Res. 2003 9 4324-4331
48. Topol E.J. Failing the public health-rofecoxib, Merck, and the FDA N. Engl. J. Med. 2004 351 1707-1709
49. Olayioye M.A. Neve R.M. Lane H.A. Hynes N.E. The ErbB signaling network: Receptor heterodimerization in development and cancer EMBO J. 2000 19 3159-3167
50. Mathur S.P. Mathur R.S. Young R.C. Cervical epidermal growth factor-receptor (EGF-R) and serum insulin-like growth factor II (IGF-II) levels are potential markers for cervical cancer Am. J. Reprod. Immunol. 2000 44 222-230
51. Kersemaekers A.M. Fleuren G.J. Kenter G.G. et al. Oncogene alterations in carcinomas of the uterine cervix: Overexpression of the epidermal growth factor receptor is associated with poor prognosis Clin. Cancer Res. 1999 5 577-586
52. Janmaat M.L. Giaccone G. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors Oncologist 2003 8 576-586
53. Nasu S. Ang K.K. Fan Z. Milas L. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability Int. J. Radiat. Oncol. Biol. Phys. 2001 51 474-477
54. Pillai M.R. Jayaprakash P.G. Nair M.K. Tumour-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix J. Cancer Res. Clin. Oncol. 1998 124 456-461
55. Janmaat M.L. Giaccone G. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy Drugs Today (Barc) 2003 39 SUPPL. C 61-80
56. JA Bonner J Giralt PM Harari Cetuximab prolongs survival in patients with looregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab Proc Am Soc Clin Oncol 22 2004 abstr 5507
57. Lynch T.J. Bell D.W. Sordella R. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 2004 350 2129-2139
58. Chavez-Blanco A. Perez-Sanchez V. Gonzalez-Fierro A. et al. HER2 expression in cervical cancer as a potential therapeutic target BMC Cancer 2004 4 59
59. LeRoith D. Roberts Jr. C.T. The insulin-like growth factor system and cancer Cancer Lett. 2003 195 127-137
60. Mitsiades C.S. Mitsiades N. Poulaki V. et al. Activation of NF-κB and upregulation of intracellular antiapoptotic proteins via the IGF-1/ Akt signaling in human multiple myeloma cells: Therapeutic implications Oncogene 2002 21 5673-5683
61. Brodt P. Samani A. Navab R. Inhibition of the type I insulin-like growth factor receptor expression and signaling: Novel strategies for antimetastatic therapy Biochem. Pharmacol. 2000 60 1101-1107
62. Nakamura K. Hongo A. Kodama J. et al. Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines Cancer Res. 2000 60 760-765
63. Steller M.A. Delgado C.H. Bartels C.J. et al. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells Cancer Res. 1996 56 1761-1765
64. Mathur S.P. Mathur R.S. Underwood P.B. et al. Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer Gynecol. Oncol. 2003 91 486-493
65. Mathur S.P Landen C.P. Datta S.M. et al. Insulin-like growth factor II in gynecological cancers: A preliminary study Am. J. Reprod. Immunol. 2003 49 113-119
66. Renehan A.G. Zwahlen M. Minder C. et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis Lancet 2004 363 1346-1353
67. Wu X. Tortolero-Luna G. Zhao H. et al. Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix Clin. Cancer Res. 2003 9 3356-3361
68. Zhang H.G. Wang J. Yang X. et al. Regulation of apoptosis proteins in cancer cells by ubiquitin Oncogene 2004 23 2009-2015
69. Johnson T.R. Stone K. Nikrad M. et al. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells Oncogene 2003 22 4953-4963
70. Liu X. Yue P. Zhou Z. et al. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells J. Natl. Cancer Inst. 2004 96 1769-1780
71. He Q. Luo X. Huang Y. Sheikh M.S. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells Oncogene 2002 21 6032-6040
72. Kim G.E. Kim Y.B. Cho N.H. et al. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: A potential predictor of poor survival Clin. Cancer Res. 2004 10 1366-1374
73. Park S.Y. Seol D.W. Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis Biochem. Biophys. Res. Commun. 2002 295 515-518
74. Poulaki V. Mitsiades C.S. Kotoula V. et al. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells Am. J. Pathol. 2002 161 643-654